1. Analysis
1.1. Hospital
1.1.1. DDD Market (Run rate)
1.1.1.1. Dengvaxia....units / month
1.1.1.2. Qdenga.....units / month
1.1.1.3. Flu.....units / month
1.1.1.4. HPV.....units / month
1.1.1.5. PCV ... units / month
1.1.1.6. Zoster ... units / month
1.1.2. Hospital class ...
1.1.3. Qdenga price to patient
1.1.3.1. 1 dose ... THB
1.1.3.2. Qdenga package (2 doses) ... THB
1.1.3.3. Special campaign ... THB
1.2. Customer
1.2.1. Social style
1.2.2. Doctor class ....
1.2.3. Adoption level
1.2.3.1. Strategy to approach
1.2.3.1.1. Advocacy
1.2.3.1.2. Adoption
1.2.3.1.3. Trial
1.2.3.1.4. Product Awareness
1.2.3.1.5. Disease Awareness
1.2.3.2. Rate per month ..... units
1.3. HCPs engagement plan
1.3.1. Personal information, preference
1.3.2. Educational sponsorship
1.3.2.1. Local congress
1.3.2.2. Oversea congress
1.3.2.3. Hospital congress
1.3.3. Optimized time allocation and resource
1.3.3.1. Call/month
1.3.3.2. Speaker program
1.3.3.3. Sample
1.3.4. Omnichannel engagement
1.3.4.1. QdengueHub
1.3.4.1.1. Approval email
1.3.4.1.2. Live webinar
1.3.4.1.3. Rerun symposium
1.3.4.1.4. Short-video
1.3.4.1.5. Proceeding
1.3.4.2. Qdengue X
1.3.4.3. KnowDengueTH
2. Recommend Dengue Vaccines
2.1. Recommended (Adoption level - Trial / Adoption / Advocacy)
2.2. Not Recommended yet
2.2.1. Reason to not recommended
2.2.1.1. No time
2.2.1.2. Financial issue
2.2.1.3. Not responsibility
2.2.1.4. Not aware about "Dengue burden"
2.2.1.5. Need more info about "Dengue vaccine"
2.2.2. What vaccines do HCP recommend
2.2.2.1. Influenza vaccine
2.2.2.2. Pneumococcal vaccine
2.2.2.3. Zoster vaccine
2.2.2.4. COVID-19 vaccine
2.2.2.5. HPV vaccine
2.2.2.6. Not recommend any vaccine
3. The Fundamental Element
3.1. Disease
3.1.1. Check list - Who are at risk
3.1.2. Co-morbidities
3.1.3. Thailand: Dengue situation
3.1.4. Severity --> leading to Dead
3.1.5. High burden - Dengue serotype 1 & 2
3.2. Efficacy
3.2.1. DEN 301
3.2.1.1. Overall Efficacy
3.2.1.2. Efficacy by baseline serostatus
3.2.1.3. Efficacy by baseline serotype
3.2.1.4. Immunogenicity
3.2.1.5. Interdose efficacy
3.2.2. DEN 304
3.2.2.1. Immunobrigding
3.3. Safety
3.3.1. Adverse event
3.3.2. Long-term safety
3.3.2.1. Long term safety follow up 4.5 year
3.3.2.2. No Serious Adverse event
3.3.2.3. No difference between TDV and Placebo
3.3.3. Real world PV
3.3.3.1. Consistance with the clinical trial
3.4. Dose/Administration
3.4.1. Normal regimen - 2 doses (0.3)
3.4.2. SC route
3.5. MOA
3.5.1. Structure
3.6. Co-Administration with other vaccine
3.7. Cost
3.7.1. Cost of Dengue admission
3.8. FAQ
4. Prescription Opportunity
4.1. PED Doctor
4.1.1. Request by patients
4.1.2. Patient with previous dengue infection
4.1.2.1. Patient
4.1.2.2. Caregiver
4.1.3. Recommend with other vaccine
4.1.4. All Children >= 4 years old
4.1.5. Advice [Parents]
4.2. Adult Doctor
4.2.1. Request by patients
4.2.2. Patient with previous dengue infection
4.2.2.1. Patients
4.2.2.2. Caregiver
4.2.3. Early start in Adult patients with co-mobidity
4.2.4. Recommend with other vaccine
4.2.5. Adult who living with children and caregiver
4.2.6. Healthy adult
4.2.6.1. Check up
4.3. IB / EP
4.3.1. Project QDENGA for employee (IB/EP)
4.3.1.1. Received "Annual Flu vaccination"
4.3.1.2. Optimal size of company
4.3.1.3. Wellingness to provide the wellness benefits to employees
4.3.1.4. Be a hospital partner (Annual health check up)
5. Willingness to pay
5.1. Not willingness .....%
5.2. Potential patient (Self-paid 100%) .....%
5.2.1. Government
5.2.1.1. OPD ... %
5.2.1.2. Premiun clinic ... %
5.2.1.3. Check up / Well-baby ... %
5.2.1.4. IPD ... %
5.2.2. Private
5.2.2.1. OPD ... %
5.2.2.2. Check up/ Well-baby ... %
5.2.2.3. IPD ... %
5.2.3. Doctor own clinic
5.2.3.1. ... %